News
SAGE
9.21
+0.49%
0.05
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
Benzinga · 1d ago
Sage Therapeutics Price Target Cut to $9.20/Share From $12.00 by Scotiabank
Dow Jones · 1d ago
Sage Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank
Dow Jones · 1d ago
Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2
Benzinga · 1d ago
SAGE THERAPEUTICS INC <SAGE.O>: SCOTIABANK CUTS TO SECTOR PERFORM FROM SECTOR OUTPERFORM; CUTS TARGET PRICE TO $9.2 FROM $12
Reuters · 1d ago
Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
TipRanks · 1d ago
Weekly Report: what happened at SAGE last week (0630-0704)?
Weekly Report · 2d ago
Sage Therapeutics cutting over 330 jobs, Boston Globe reports
TipRanks · 07/01 13:30
Weekly Report: what happened at SAGE last week (0623-0627)?
Weekly Report · 06/30 10:19
Weekly Report: what happened at SAGE last week (0616-0620)?
Weekly Report · 06/23 10:15
Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
TipRanks · 06/22 18:25
J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)
TipRanks · 06/22 18:16
Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
TipRanks · 06/21 09:01
Sage Therapeutics Is Maintained at Neutral by Baird
Dow Jones · 06/20 13:48
Baird Maintains Neutral on Sage Therapeutics, Raises Price Target to $9
Benzinga · 06/20 13:38
Sage Therapeutics price target raised to $9 from $7 at Baird
TipRanks · 06/20 10:45
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Barchart · 06/18 22:03
Analysts’ Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)
TipRanks · 06/18 09:10
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)
Benzinga · 06/17 19:00
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
NASDAQ · 06/17 18:36
More
Webull provides a variety of real-time SAGE stock news. You can receive the latest news about Sage Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.